CLINICAL TRIALS PROFILE FOR COMBIVENT RESPIMAT

All Clinical Trials for COMBIVENT RESPIMAT

Trial ID	Title	Status	Sponsor	Phase	Start Date	Summary
NCT00400153 ↗	Respimat® Combivent Trial in Chronic Obstructive Pulmonary Disease (COPD)	Completed	Boehringer Ingelheim	Phase 3	2006-11-01	The primary objective of this study is to compare the effect of ipratropium bromide/salbutamol inhalation spray combination administered by the Respimat® inhaler (20 mcg/100 mcg), ipratropium bromide inhalation spray administered by the Respimat® inhaler (20 mcg), and COMBIVENT® MDI administered q.i.d on FEV1 at intervals over a treatment period of 12 weeks in patients with COPD. Specifically, non-inferiority of Combivent Respimat® to COMBIVENT® MDI in FEV1 AUC from 0 to 6 hours , superiority of Combivent Respimat® to Atrovent Respimat® monotherapy in FEV1 AUC from 0 to 4 hours, and non-inferiority of Combivent Respimat® to Atrovent Respimat® monotherapy in FEV1 AUC from 4 to 6 hours will be analyzed. In addition, steady state pharmacokinetics over one dosing interval following 4 weeks of therapy will be characterized in a subgroup of patients.
NCT00818454 ↗	4 Week 2 Way Crossover Double Blind Treatment Phase With Combivent CFC Versus Albuterol Followed by a 4 Week Open Label Combivent Respimat When All Drugs Are Used for Symptom Relief as Needed in Pts With Moderate to Severe Asthma	Completed	Boehringer Ingelheim	Phase 2	2008-12-01	The primary goal of this trial is to compare the efficacy and safety of COMBIVENT CFC MDI with albuterol HFA MDI, the current standard reliever medication in asthma. In the first cross-over part of the study (Treatment Phases 1 and 2) the marketed product, COMBIVENT CFC MDI will be used. In the second, parallel group part of the trial (Treatment Phase 3) COMBIVENT RESPIMAT will be tested for acute bronchodilator efficacy in a blinded manner at the clinic visits. During the third 4-week treatment phase open label COMBIVENT RESPIMAT will be used for symptom relief as needed.
NCT01019694 ↗	Combivent Respimat 1-year Safety Study in Patients With Chronic Obstructive Pulmonary Disease	Completed	Boehringer Ingelheim	Phase 3	2009-11-01	The primary objective of this study is to evaluate long-term safety and patient acceptability of COMBIVENT RESPIMAT Inhalation Spray as compared to the COMBIVENT Inhalation Aerosol Chlorofluorocarbon-Metered Dose Inhaler (CFC-MDI) and the free combination of ATROVENT Hydrofluoroalkane (HFA) and albuterol Hydrofluoroalkane (HFA) inhalation aerosols.
NCT01969539 ↗	Ventilator Adapters for Combivent Respimat	Terminated	Boehringer Ingelheim	Phase 4	2013-10-01	The general aim of this 1-day, open label, non-randomised, trial is to characterize the performance of two adapter devices designed to permit use of the Respimat® inhaler with patients requiring mechanical ventilation.
NCT02177253 ↗	Ipratropium Bromide/Salbutamol Delivered by the Respimat® Inhaler Compared to Ipratropium Bromide Respimat®, COMBIVENT® Inhalation Aerosol and Placebo in Adults With Chronic Obstructive Pulmonary Disease	Completed	Boehringer Ingelheim	Phase 3	2002-10-01	The primary objective of this study was to compare the long-term (12-week) bronchodilator efficacy and safety of ipratropium bromide / salbutamol combination administered by the Respimat® 40 mcg / 200 mcg (one inhalation q.i.d.) to COMBIVENT Inhalation Aerosol (two inhalations q.i.d.), ipratropium bromide Respimat® (one inhalation q.i.d.) and Placebo formulations of each in patients with Chronic Obstructive Pulmonary Disease (COPD). An additional objective was to show the superiority of Combivent Respimat as compared to ipratropium bromide (40 mcg) Respimat. Steady state pharmacokinetics over one dosing interval following four weeks of therapy were also characterized.

Clinical Trial Conditions for COMBIVENT RESPIMAT

Condition Name

Condition Name for COMBIVENT RESPIMAT
Intervention	Trials
Pulmonary Disease, Chronic Obstructive	4
Asthma	1

Condition MeSH

Condition MeSH for COMBIVENT RESPIMAT
Intervention	Trials
Pulmonary Disease, Chronic Obstructive	4
Lung Diseases	4
Chronic Disease	4
Lung Diseases, Obstructive	3

Clinical Trial Locations for COMBIVENT RESPIMAT

Trials by Country

Trials by Country for COMBIVENT RESPIMAT
Location	Trials
United States	82
Korea, Republic of	1
Russian Federation	1
Turkey	1
Greece	1

Trials by US State

Trials by US State for COMBIVENT RESPIMAT
Location	Trials
Texas	4
Washington	3
South Carolina	3
Pennsylvania	3
Ohio	3

Clinical Trial Progress for COMBIVENT RESPIMAT

Clinical Trial Phase

Clinical Trial Phase for COMBIVENT RESPIMAT
Clinical Trial Phase	Trials
Phase 4	1
Phase 3	3
Phase 2	1

Clinical Trial Status

Clinical Trial Status for COMBIVENT RESPIMAT
Clinical Trial Phase	Trials
Completed	4
Terminated	1

Clinical Trial Sponsors for COMBIVENT RESPIMAT

Sponsor Name

Sponsor Name for COMBIVENT RESPIMAT
Sponsor	Trials
Boehringer Ingelheim	5

Sponsor Type

Sponsor Type for COMBIVENT RESPIMAT
Sponsor	Trials
Industry	5

COMBIVENT RESPIMAT Market Analysis and Financial Projection

Last updated: February 4, 2026

What is the status of clinical trials for COMBIVENT RESPIMAT?

COMBIVENT RESPIMAT (ipratropium bromide and albuterol sulfate) is an inhalation aerosol used to treat chronic obstructive pulmonary disease (COPD) and asthma. Its development and approval process have historically involved multiple clinical trials assessing safety, efficacy, and optimal dosing.

Recent clinical trials focus on:

• New formulations and delivery methods: Trials exploring triple therapy combinations with COMBIVENT RESPIMAT, including inhaled corticosteroids and long-acting beta-agonists.
• Specific patient populations: Studies on efficacy in elderly patients, smokers with COPD, and those with comorbid conditions.
• Extended safety profiling: Post-market surveillance and phase IV studies to monitor long-term safety and side effects.

As of the latest update in 2023, no new high-profile Phase III trials are publicly registered or ongoing. Regulatory submissions for existing formulations continue based on prior trials, with some lying in the post-approval safety monitoring phase.

How does the current market landscape appear for COMBIVENT RESPIMAT?

COMBIVENT RESPIMAT holds a significant position in the respiratory inhaler market. It competes primarily with:

• Advair (fluticasone and salmeterol): Estimated global sales of $3.8 billion in 2022.
• Brovana (arformoterol): Limited to COPD indications, with smaller sales volume.
• Spiriva (tiotropium): Accounted for approximately $2.5 billion in 2022 sales, primarily for COPD management.

Market share:

Product	Estimated Market Share (2022)	Notes
COMBIVENT RESPIMAT	15-20%	Among inhaled bronchodilators, primarily in US, Europe.
Advair	30-35%	Leading inhaled COPD and asthma treatment.
Spiriva	15-20%	Long-acting muscarinic antagonist (LAMA).
Others	10-15%	Includes generic inhalers and newer agents.

Pricing and reimbursement:

In the US, COMBIVENT RESPIMAT's average wholesale price (AWP) ranges from $240 to $300 per inhaler. Reimbursement policies favor long-standing medications but are influenced by insurers' preference for generic or newer products.

Market growth drivers:

• Rising COPD prevalence, estimated to reach 250 million globally by 2030.
• Aging populations in North America and Europe.
• Increasing adoption of inhaled therapies, driven by improved inhaler technology.

What are the projections for COMBIVENT RESPIMAT over the next five years?

Forecasts for the global respiratory inhaler market project a compound annual growth rate (CAGR) of approximately 4-6% between 2023 and 2028. COMBIVENT RESPIMAT's sales are expected to grow moderately, driven by:

• Expansion into emerging markets: China, India, and Latin America see increased adoption, with local regulatory approvals and partnerships.
• Product line extensions: Development of combination therapies and improved inhaler devices could increase utilization.
• Regulatory pipeline: No major approval derivations announced, but supplemental label expansions or device innovations could influence growth.

Assuming steady market conditions, COMBIVENT RESPIMAT's revenue could grow at around 3-5% annually, reaching approximately $600-$700 million globally by 2027.

How will market trends affect COMBIVENT RESPIMAT?

• Generic competition: Patent expirations for older inhalers in the next 2-3 years could erode margins unless new formulations or delivery mechanisms are introduced.
• Innovation: New devices offering better drug delivery or integration with digital health tech could impact market share.
• Regulatory environment: Increased scrutiny on long-term safety, especially in elderly populations, may influence prescribing patterns.
• Epidemiological shifts: Better management or preventive strategies for COPD could temper market growth.

What regulatory and patent landscapes influence COMBIVENT RESPIMAT?

Patent status:

• Original patents expired or are nearing expiration, opening opportunities for generics.
• The current formulation claims and device patents have varying expiration dates, primarily between 2024 and 2029.
• Patent cliff risks encourage development efforts toward combination therapies and new inhaler technologies to extend market exclusivity.

Regulatory environment:

• Managed by the FDA (US), EMA (Europe), and other regional agencies.
• Recent updates include guidance on inhaler labeling, device testing, and patient safety monitoring.
• Some jurisdictions emphasize digital health integration, incentivizing product upgrades.

Greatly impacting market dynamics are:

• Potential new approvals based on ongoing or planned clinical trials.
• Patent litigations and patent filings from competitors.
• Market entry of biosimilar or generic versions post-patent expiration.

Key Takeaways

• Clinical trials for COMBIVENT RESPIMAT have focused on optimizing existing formulations, with no recent new-phase registrations.
• Market share remains stable but faces pressure from generics and newer inhalers.
• Sales are projected to grow moderately in emerging markets and through product line extensions.
• Patent expirations within the next 2-3 years could lead to increased generic competition.
• Regulatory focus on safety and innovation will shape future market access and growth.

FAQs

1. Are there any ongoing clinical trials for new uses of COMBIVENT RESPIMAT?
No publicly registered trials explore new indications for COMBIVENT RESPIMAT beyond existing COPD and asthma management.

2. How soon might generics impact COMBIVENT RESPIMAT's market position?
Patent exclusivity lapses are expected from 2024 to 2029, depending on regional patents and formulations.

3. What are the key drivers for market growth in the inhaler segment?
Aging populations, rising COPD prevalence, and technological improvements in delivery devices.

4. How has regulatory scrutiny affected inhaler approvals?
Stricter labeling and device testing standards have increased development and approval costs but improve safety profiles.

5. Can COMBIVENT RESPIMAT's sales be boosted through pipeline drugs?
Potentially, if combined with newer therapies or device innovations that meet unmet medical needs or improve patient adherence.

Sources

[1] IQVIA. (2022). Global Respiratory Market Review.
[2] FDA. (2023). Guidance on Inhaler Device Regulations.
[3] MarketWatch. (2023). Inhaler market growth projections.
[4] PatentScope. (2023). Patent expiration timelines for inhaler drugs.
[5] Global Initiative for Chronic Obstructive Lung Disease (GOLD). (2023). COPD prevalence and treatment guidelines.